Skip to main content

Table 2 Baseline data

From: Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study

Hemoglobin (g/dL)

13.8 ± 1.2

Albumin (g/dL)

4.2 ± 0.3

Triglyceride (mg/dL)

136 ± 82

alkaline phosphatase (IU/L)

223 ± 59

Blood urea nitrogen (mg/dL)

15 ± 3

Creatinine (mg/dL)

0.74 ± 0.24

ucOC (ng/ml)

3.7 ± 2.5

OC (ng/ml)

7.5 ± 2.7

ucOC/OC ratio

0.46 ± 0.18

PIVKA2 (mAU/mL)

19 ± 7

intact parathyroid horomone (pg/mL)

38.9 ± 22.0

Bone specific alkaline phosphatase (μg/l)

13.8 ± 6.5

NTX (nmol BCE/L)

16.9 ± 5.1

high sensitive C-reactive protein (mg/L)

929 ± 1132

Osteoprotegerin (ng/mL)

91.7 ± 30.8

oxidized low density lipoprotein (μg/dL)

104.9 ± 11.9

t-ucMGP (nmol/L)

2907 ± 1333

PK (ng/mL)

1.94 ± 1.38

MK-7 (ng/mL)

14.2 ± 11.9

MK-4 (ng/mL)

0.4 ± 2.0

  1. ucOC uncarboxylated osteocalcin
  2. OC osteocalcin
  3. PIVKA2 protein induced by vitamin K absence or antagonist- 2
  4. NTX collagen type 1 cross-linked N-telopeptide
  5. t-ucMGP total circulating uncarboxylated matrix gla protein
  6. PK philloquinone, MK menaquinone